" A United Nations panel recently released disastrous policy recommendations designed to increase access to medicines in developing countries. The panel ignored obvious solutions. Secretary General Ban Ki-Moon originally tasked the UN High-Level Panel on Access to Medicines with remedying the “policy incoherence” between intellectual property rights and drug access. The panel predictably — and wrongly — viewed IP protections as a barrier to access rather than a bridge to medical innovation. Undermining IP rights will not help patients in developing countries access medicines. A 2016 Foreign Affairs study sought to determine whether strong patent protections increase the prices of drugs to developing countries. It found that patents were not key drivers of higher expenditures."
Ethically-tangled aspects of 21st century societies and cultures. In the vein of Charles Darwin’s 1859 “entangled bank” metaphor—a complex and evolving digital ecosystem of difference and dependence, where humans, technologies, ethics, law, policy, data, and information converge and diverge. Kip Currier, PhD, JD
Showing posts with label drivers of drug prices. Show all posts
Showing posts with label drivers of drug prices. Show all posts
Wednesday, November 2, 2016
Patent rights key to ensuring access to medication; Trib Live, 10/24/16
Robert A. Freeman, Trib Live; Patent rights key to ensuring access to medication:
Subscribe to:
Posts (Atom)